• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Investing

Why is SLS stock soaring over 220% on Tuesday?

by November 17, 2026
written by November 17, 2026

Shares of Sellas Life Sciences SLS surged more than 220% at market open on Tuesday after the drug developer reported positive results from a late-stage trial of its experimental cancer vaccine, which significantly extended survival among patients with acute myeloid leukemia (AML).

The vaccine, called galinpepimut-S (GPS), reduced the risk of death by 41% compared with the best available treatment in a study involving 126 patients, the company said.

Patients who received GPS recorded a median overall survival of 24 months, against 14.7 months among those in the control group.

Trading in Sellas shares was halted during premarket hours following the sharp rise.

Vaccine shows survival benefit in AML patients

The trial evaluated GPS in patients with AML who had achieved remission following cancer treatment but were unable to undergo a bone marrow or stem cell transplant.

AML is an aggressive cancer affecting the blood and bone marrow.

Patients whose disease returns after treatment often have limited therapeutic options, making the development of treatments that can prolong survival particularly important.

GPS is designed to train the immune system to identify and attack residual leukemia cells carrying a protein known as WT1.

Sellas said the vaccine was generally well tolerated and did not raise any new safety concerns.

Most reported side effects were mild to moderate, with injection-site reactions being the most common.

“The magnitude of the survival benefit observed with our investigational GPS immunotherapeutic cancer vaccine represents a defining milestone for Sellas,” CEO Angelos Stergiou said.

The scale of the potential patient population is significant.

According to the American Cancer Society, about 22,720 people in the US are expected to be diagnosed with AML in 2026, while approximately 11,500 are projected to die from the disease, Reuters reported.

AML accounts for one in three adult leukemia cases.

Sellas targets FDA discussions and 2027 filing

Sellas plans to meet with the US Food and Drug Administration (FDA) to discuss the trial findings and an accelerated regulatory strategy.

The company is preparing for a Biologics License Application (BLA) submission in the first half of 2027.

“Given the significant unmet need in this patient population, we look forward to engaging with the FDA to discuss the results and the regulatory path forward, with the goal of making this therapy available to patients as rapidly as possible,” Stergiou said.

The regulatory discussions will be an important next step as the company seeks to translate the trial results into a potential treatment option.

The findings do not, however, mean that GPS has received regulatory approval.

Company advances another leukemia drug candidate

The latest development comes as Sellas continues to advance its broader oncology pipeline.

Earlier this month, the company reported a net loss of $10.1 million, or $0.05 per share, compared with a loss of $6.8 million, or $0.06 per share, a year earlier.

Sellas reported no revenue, in line with analyst expectations.

Its smaller loss per share came despite the increase in its overall loss, as weighted-average shares outstanding rose to approximately 202.4 million from 108.4 million.

Last week, Sellas also said that 40 patients had enrolled in an 80-patient Phase 2 trial of tambiciclib, also known as SLS009, in newly diagnosed AML.

Preliminary results are expected in the fourth quarter.

Separately, the company plans to present completed Phase 2 findings for SLS009 in relapsed or refractory leukemia at the American Society of Hematology meeting in December.

Sellas has reported response rates of 54% among patients with monocytic disease and 57% among those with TP53-mutated disease.

The GPS results have given Sellas a significant clinical milestone, although the company’s next challenge will be securing a regulatory pathway for the vaccine and demonstrating that the survival benefit can support its eventual approval.

AI disclosure: AI tools assisted with research and drafting of this piece. An Invezz editor reviewed the facts, sources and wording before publication. Any opinions or analysis are Invezz’s, not those of an automated system.

The post Why is SLS stock soaring over 220% on Tuesday? appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Why is Intel stock falling on Tuesday?
next post
Nasdaq slips as Wall Street awaits Nvidia earnings and Anthropic IPO

related articles

Nvidia stock rises after hours as revenue forecast...

November 17, 2026

Why this analyst sees a 30% upside for...

November 17, 2026

Netflix stock analysis: what next for this fallen...

November 17, 2026

Evening digest: Huang says he is prepared to...

November 17, 2026

Salesforce stock slides as technology outages rattle software...

November 17, 2026

Micron stock falls 2%, why this analyst cut...

November 17, 2026

Nebius stock is falling: Here’s why NBIS may...

November 17, 2026

Nike outlines $5B growth plan as turnaround faces...

November 17, 2026

Jensen Huang keeps door open to return as...

November 17, 2026

Why SpaceX stock is rising on Tuesday?

November 17, 2026
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Kospi Index rebounds as Samsung and SK Hynix rally: is the tide finally turning?

    July 15, 2026
  • Oracle stock in green despite reported $7B Tencent chip deal cancellation

    November 4, 2026
  • EU ramps up pressure on Meta over child safety concerns

    June 23, 2026
  • Socialists capture major Florida victory on hit-or-miss night for Trump-endorsed primary candidates

    August 19, 2026
  • Lumentum stock rises 6% as AI demand fills optical orders through 2029

    October 9, 2026

Popular Posts

  • 1

    Why SpaceX stock is down around 3% on Tuesday

    September 15, 2026
  • 2

    Micron stock falls 4%, why this analyst sees 40% upside for the stock?

    September 28, 2026
  • 3

    Evening digest: US jobs cool, gold falls as Treasury yields rise

    October 2, 2026
  • 4

    Intel, AMD stocks slide again in aftermath of Broadcom’s weak outlook

    June 5, 2026
  • 5

    Nike stock sinks after earnings as its comeback plan turns into more layoffs

    October 2, 2026

Categories

  • Editor's Pick (711)
  • Investing (2,601)
  • Stock (90)

Latest Posts

  • Intel gains before opening bell: How Musk’s comments became a catalyst

    October 7, 2026
  • Solidion stock announces space pivot ahead of SpaceX IPO: but will the gains last?

    June 4, 2026
  • AST SpaceMobile stock rises after SpaceX launches BlueBird satellites

    June 17, 2026

Recent Posts

  • Evening digest: Anthropic launches Claude Opus 5.5, oil falls below $100

    September 22, 2026
  • Micron, SanDisk stocks jump after 15% and 18% crashes: what sparked the comeback?

    October 19, 2026
  • Neonatologist sounds alarm over Massachusetts abortion law allowing procedures up to birth: ‘Very disturbing’

    August 18, 2026

Editor’s Pick

  • Accenture stock plunges as Wall Street cuts targets

    June 22, 2026
  • Top DAX Index stocks for July: Volkswagen, Rheinmetall, Deutsche Bank, Zalando

    July 1, 2026
  • Netflix needs a new growth story to halt its stock decline

    June 23, 2026
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock